Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.55 |
| ▸ | CHRNA5 | P30532 | 3/20 | 0.55 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6712904 | 0.99 | CHRNB2 (0.54) | CHRNB2CHRNA7CHRNA4CHRNA5CARM1 | |
| SCHEMBL6708297 | 0.81 | DRD2 (0.47) | CHRNB2CHRNA7CHRNA4CHRNA5NPC1 | |
| Hydrochloric Acid SCHEMBL6709532 | 0.80 | DRD2 (0.46) | CHRNB2CHRNA7CHRNA4CHRNA5NPC1 | |
| Hydrochloric Acid SCHEMBL6709530 | 0.74 | SIGMAR1 (0.46) | CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL8045838 | 0.71 | KCNH2 (0.57) | CHRNA7 | |
| SCHEMBL8045835 | 0.71 | KCNH2 (0.57) | CHRNA7 | |
| SCHEMBL6707464 | 0.70 | CHRNB2 (0.45) | CHRNB2CHRNA7CHRNA4CHRNA5CARM1 | |
| SCHEMBL8447322 | 0.70 | CARM1 (0.61) | CHRNB2CHRNA7CHRNA4CHRNA5CARM1 | |
| SCHEMBL532785 | 0.70 | CARM1 (0.61) | CHRNB2CHRNA7CHRNA4CHRNA5CARM1 | |
| Hydrochloric Acid SCHEMBL6709597 | 0.69 | CHRNB2 (0.44) | CHRNB2CHRNA7CHRNA4CHRNA5CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | MERCK PATENT GMBH (DE) | 2004-06-10 | — | — | US | claimed |
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | MERCK PATENT GMBH (DE) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | CHRNA1, CHRNA2, CHRNA10 | CHRNB2 11/4885CHRNA7 8/4885CHRNA4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.